natgillin/translations-raw huggingface dataset:
Darunavir 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen.
Tablete darunavir od 400 mg i 800 mg mogu se uzimati za dostizanje jednokratne doze od 800 mg.
Each film-coated tablet contains 600 mg of darunavir.
Jedna filmom obložena tableta sadrži 600 mg darunavira.
800 mg darunavir/100 mg ritonavir once daily
800 mg darunavir/100 mg ritonavir jedanput na dan
Darunavir Mylan 400 mg film-coated tablets Each film-coated tablet contains 400 mg of darunavir.
Darunavir Mylan 400 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 400 mg darunavira.
#darunavir Cmax ↔
#darunavir AUC ↔ #darunavir Cmin ↔ darunavir Cmax ↔
- In the evening, take 600 milligram darunavir together with 100 milligram ritonavir.
- Navečer uzmite 600 miligrama darunavira zajedno sa 100 miligrama ritonavira.
If efavirenz is to be used in combination with darunavir, the darunavir/ritonavir 600/100 mg twice daily regimen should be used (see section 4.5).
Ako je potrebno primjenjivati efavirenz u kombinaciji s darunavirom, za darunavir/ritonavir mora se primijeniti režim od 600/100 mg dva puta na dan. (vidjeti dio 4.5).
Darunavir Mylan 75 mg film-coated tablets are white to off-white, oval shaped with two curved sides, marked with M on one side and DV1 on the other side.
Darunavir Mylan 75 mg filmom obložene tablete bijele su do gotovo bijele boje, ovalnog oblika s dvije zaobljene strane i označene su s M na jednoj strani i DV1 na drugoj strani.
copies/ml and CD4+ cell count ≥ 100 cells x 10
CD4+ stanica ≥ 100 stanica x 10
Darunavir Mylan 150 mg film-coated tablets EU/1/16/1140/006
Darunavir Mylan 150 mg filmom obložene tablete EU/1/16/1140/006
Darunavir AUC24h ↑ 33% (based on population pharmacokinetic model)
Istodobna sistemska primjena klotrimazola i pojačanog darunavira može povisiti koncentracije darunavira i/ili klotrimazola u plazmi. darunavir AUC24h ↑ 33% (na temelju populacijskog farmakokinetičkog modela)
darunavir/ ritonavir 800/100 mg once daily N=343
Darunavir/ ritonavir 800/100 mg jedanput na dan n=343
Rare dyspnoea, cough, epistaxis, throat irritation rhinorrhoea
Poremećaji dišnog sustava, prsišta i sredoprsja manje često rijetko dispneja, kašalj, epistaksa, nadraženost grla rinoreja
A dosage reduction of rifabutin by 75% of the usual dose of 300 mg/day (i.e. rifabutin 150 mg once every other day) and increased monitoring for rifabutin related adverse events is warranted in patients receiving the combination with darunavir coadministered with ritonavir.
Kod bolesnika koji primaju kombinaciju lijekova s darunavirom istodobno primijenjenog s ritonavirom potrebno je 75% smanjenje doze rifabutina u odnosu na uobičajenu dozu od 300 mg/dan (npr. rifabutin 150 mg jedanput svaki drugi dan) te pojačano praćenje štetnih događaja povezanih s rifabutinom.
Bottle carton
Kutija za bocu
Bottle carton 30 film-coated tablets 120 film-coated tablets
Kutija za bocu 30 filmom obloženih tableta 120 filmom obloženih tableta
Concomitant use of darunavir co-administered with low dose ritonavir with lovastatin and simvastatin is therefore contraindicated (see section 4.3).
Istodobna primjena darunavira primijenjenog istodobno s niskom dozom ritonavira s lovastatinom i simvastatinom je zbog toga kontraindicirana (vidjeti dio 4.3).
Darunavir Mylan 300 mg film-coated tablets Each film-coated tablet contains 300 mg of darunavir.
Darunavir Mylan 300 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 300 mg darunavira.
- In the evening, take two 300 milligram darunavir tablets together with 100 milligram ritonavir.
- Navečer uzmite dvije tablete darunavira od 300 miligrama zajedno sa 100 miligrama ritonavira.
Concomitant use of darunavir coadministered with low dose ritonavir and these antidepressants may increase concentrations of the antidepressant.
Istodobno uzimanje darunavira istodobno primijenjenog s niskom dozom ritonavira i tih antidepresiva može povećati koncentracije antidepresiva. (CYP2D6 i/ili CYP3A inhibicija)
Treatment-experienced darunavir/cobicistat 800/150 mg once daily + OBR N=18
Prethodno liječeni darunavir/kobicistat 800/150 mg jedanput na dan + OOR N=18
The effects of other medicines might be influenced if you take darunavir.
Ako uzimate lijek darunavir to može utjecati na učinke drugih lijekova.
- In the morning, take two 300 milligram darunavir tablets together with 100 milligram ritonavir.
- Ujutro uzmite dvije tablete darunavira od 300 miligrama zajedno sa 100 miligrama ritonavira.
Boosted darunavir and dolutegravir can be used without dose adjustment.
Pojačani darunavir i dolutegravir mogu se uzimati bez prilagodbe doze.
Darunavir Mylan 800 mg film-coated tablets are available in blister packs containing 30 tablets and in plastic bottles containing 30, 60 and 90 tablets.
Darunavir Mylan 800 mg filmom obložene tablete dostupne su u blister pakiranjima koja sadrže 30 tableta i plastičnim bocama koje sadrže 30, 60 i 90 tableta.
Efficacy of darunavir 800 mg once daily co-administered with 100 mg ritonavir once daily in ARTnaïve patients
Djelotvornost darunavira od 800 mg jedanput na dan primijenjenog istodobno sa 100 mg ritonavira jedanput na dan u bolesnika prethodno liječenih ART-om
It is not recommended to combine darunavir co-administered with low dose ritonavir with saquinavir.
Ne preporučuje se istodobna primjena darunavira istodobno primijenjenog s niskom dozom ritonavira u kombinaciji sa sakvinavirom.
CD4+ cell count mean change from baseline b
Postotak promjene CD4+ od početne vrijednosti b
Concomitant use of colchicine and darunavir coadministered with low dose ritonavir may increase the exposure to colchicine.
Istodobna primjena kolhicina i darunavira primijenjenog istodobno s niskom dozom ritonavira može povećati izloženost kolhicinu. (inhibicija CYP3A i/ili P-gp-a)
Co administration of boosted darunavir with clonazepam may increase concentrations of clonazepam.
Istovremena primjena pojačanog darunavira s klonazepamom može povećati koncentracije klonazepama. (CYP3A inhibicija)
Each film-coated tablet contains 400 mg of darunavir.
Jedna filmom obložena tableta sadrži 400 mg darunavira.
Each film-coated tablet contains 300 mg of darunavir.
Jedna filmom obložena tableta sadrži 300 mg darunavira.
The recommended dose regimen is 800 mg once daily with cobicistat 150 mg once daily or ritonavir 100 mg once daily taken with food.
Preporučeni režim doziranja je 800 mg jedanput na dan s ritonavirom od 100 mg jedanput na dan uzeto s hranom.
The Summary of Product Characteristics of ritonavir must, therefore, be consulted prior to initiation of therapy with darunavir.
Stoga se, prije početka terapije lijekom darunavir, mora pročitati Sažetak opisa svojstava lijeka za ritonavir.
Darunavir Mylan 600 mg film-coated tablets Each film-coated tablet contains 600 mg of darunavir.
Darunavir Mylan 600 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 600 mg darunavira.
- In the morning, take 600 milligram darunavir together with 100 milligram ritonavir.
- Ujutro uzmite uzmite 600 miligrama darunavira zajedno sa 100 miligrama ritonavira.
Pharmacokinetic results of total darunavir after administration of darunavir/ritonavir at 800/100 mg once daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy and postpartum
Farmakokinetički rezultati ukupnog darunavira nakon primjene darunavira/ritonavira 800/100 mg jedanput dnevno kao dijela antiretrovirusnog režima liječenja tijekom drugog trimestra trudnoće, trećeg trimestra trudnoće i postpartalnog razdoblja Farmakokinetika ukupnog darunavira (srednja vrijednost ± SD)
White to off-white, oval shaped, biconvex film-coated tablets approximately 9.7 mm by 4.6 mm, debossed with ‘M' on one side and ‘DV1' on the other side.
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 9,7 mm × 4,6 mm s utisnutom oznakom „M” na jednoj strani i „DV1” na drugoj strani.
tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% #darunavir AUC ↑ 21%
tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% darunavir AUC ↑ 21% #darunavir Cmin ↑ 24% #darunavir Cmax ↑ 16% (↑tenofovira zbog učinka na transport putem MDR-1 u bubrežnim tubulima)
Co-administration of darunavir with low dose ritonavir and alfuzosin is contraindicated (see section 4.3).
Istodobna primjena darunavira s niskom dozom ritonavira i alfuzozina je kontraindicirana (vidjeti dio 4.3).
Characteristics of ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with darunavir.
Stoga se, prije početka terapije darunavirom, mora pročitati odgovarajući Sažetak opisa svojstava lijeka za ritonavir.
Darunavir Mylan 600 mg film-coated tablets are available in blister packs containing 30 and 60 tablets and in plastic bottles containing 30, 60 and 90 tablets.
Darunavir Mylan 600 mg filmom obložene tablete dostupne su u blister pakiranjima koja sadržavaju 30 i 60 tableta i plastičnim bocama koje sadržavaju 30, 60 i 90 tableta.
Efficacy of darunavir 800 mg once daily co-administered with 150 mg cobicistat once daily in ART-naïve and ART-experienced patients
Djelotvornost darunavira od 800 mg jedanput na dan primijenjenog istodobno sa 150 mg kobicistata jedanput na dan u bolesnika prethodno neliječenih ART-om i u bolesnika prethodno liječenih ART-om
Darunavir Mylan 400 mg film-coated tablets EU/1/16/1140/022
Darunavir Mylan 400 mg filmom obložene tablete EU/1/16/1140/022
The pharmacokinetics of darunavir in combination with ritonavir taken once daily in 10 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 14 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir/ritonavir 800/100 mg once daily (see section 4.2).
Farmakokinetika darunavira u kombinaciji s ritonavirom uzetih jedanput na dan, kod 10 pedijatrijskih prethodno liječenih bolesnika, u dobi od 3 do < 6 godina i težine najmanje 14 kg do < 20 kg, pokazala je da je doziranje temeljeno na težini rezultiralo izloženošću darunaviru, sličnoj onoj postignutoj u odraslih koji su uzimali darunavir/ritonavir 800/100 mg jedanput na dan (vidjeti dio 4.2).
Treatment-naïve darunavir/cobicistat 800/150 mg once daily N=295
Prethodno nisu liječeni darunavir/kobicistat 800/150 mg jedanput na dan N=295
Twice daily dosing
Doziranje dva puta na dan Težina
Rare thrombocytopenia, neutropenia, anaemia, leucopenia increased eosinophil count
Poremećaji krvi i limfnog sustava manje često rijetko trombocitopenija, neutropenija, anemija, leukopenija povišen broj eozinofila
Otherc mean CD4+ cell count change from baseline (x 10
Srednja vrijednost promjene broja CD4+ stanica u odnosu na početni (x 10
For further information on cobicistat, consult the cobicistat Summary of Product Characteristics.
Za daljnje informacije o kobicistatu, pogledajte Sažetak opisa svojstava lijeka za kobicistat.
Darunavir Mylan 800 mg film-coated tablets EU/1/16/1140/039
Darunavir Mylan 800 mg filmom obložene tablete EU/1/16/1140/039
Darunavir is expected to increase these antineoplastic plasma concentrations.
Očekuje se da će darunavir povećati koncentracije tih antineoplastika u plazmi. (CYP3A inhibicija)
Hence, concomitant use of darunavir co-administered with low dose ritonavir and the combination product lopinavir/ritonavir is contraindicated (see section 4.3).
Odavde proizlazi da je istodobna primjena darunavira s niskom dozom ritonavira i kombiniranog lopinavira/ritonavira kontraindicirana (vidjeti dio 4.3).
Darunavir/ritonavir 800/100 mg once daily + OBR N=294
Darunavir/ritonavir 800/100 mg jedanput na dan + OOR n=294
Darunavir Mylan 150 mg film-coated tablets darunavir
Darunavir Mylan 150 mg filmom obložene tablete darunavir
Darunavir Mylan 300 mg film-coated tablets EU/1/16/1140/012
Darunavir Mylan 300 mg filmom obložene tablete EU/1/16/1140/012
White to off-white, oval shaped, biconvex film-coated tablets approximately 19.2 mm by 9.6 mm, debossed with ‘M' on one side and ‘DV4' on the other side.
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 19,2 mm × 9,6 mm s utisnutom oznakom „M” na jednoj strani i „DV4” na drugoj strani.
Darunavir co-administered with cobicistat should not be used in combination with another antiretroviral agent that requires pharmacoenhancement by means of co saquinavir/darunavir/ritonavir1,000/400/100 mg twice daily Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with saquinavir 1,000 mg twice daily.
Sakvinavir: usporedba sakvinavir/ritonavir 1000/100 mg dva puta na dan naspram sakvinavir/darunavir/ritonavir 1000/400/100 mg dva puta na dan Darunavir: usporedba darunavir/ritonavir 400/100 mg dva puta na dan naspram darunavir/ritonavir 400/100 mg u kombinaciji sa sakvinavirom 1000 mg dva puta na dan.
Number of subjects with virologic failure and paired baseline/endpoint phenotypes, showing loss of susceptibility to PIs at endpoint compared to baseline, n/N PI darunavir amprenavir atazanavir indinavir lopinavir saquinavir tipranavir a TLOVR non-VF censored algorithm based on HIV-1 RNA < 50 copies/ml, except for TITAN (HIV-1 RNA <
Broj ispitanika s virološkim neuspjehom i spareni genotip na početku/na kraju liječenja, koji su razvili mutacije b na ishodu ispitivanja, n/N Primarne (velike) IP mutacije IP RAM Broj ispitanika s virološkim neuspjehom i odgovarajući fenotip na početku/na kraju liječenja koji pokazuju gubitak osjetljivosti na IP na ishodu u usporedbi s onim na početku liječenja, n/N
Darunavir Mylan 800 mg film-coated tablets
Darunavir Mylan 800 mg filmom obložene tablete
White to off-white, oval shaped, biconvex film-coated tablets approximately 21.2 mm by 10.6 mm, debossed with ‘M' on one side and ‘DV8' on the other side.
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 21,2 mm × 10,6 mm s utisnutom oznakom „M” na jednoj strani i „DV8” na drugoj strani.
Darunavir Mylan 600 mg film-coated tablets EU/1/16/1140/030
Darunavir Mylan 600 mg filmom obložene tablete EU/1/16/1140/030
White to off-white, oval shaped, biconvex film-coated tablets approximately 21.2 mm by 10.6 mm, debossed with ‘M' on one side and ‘DV5' on the other side.
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 21,2 mm × 10,6 mm s utisnutom oznakom „M” na jednoj strani i „DV5” na drugoj strani.
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with darunavir co-administered with low dose ritonavir is required.
Ako je potrebno liječenje darunavirom istodobno primijenjenim s niskom dozom ritonavira, preporučuje se smanjiti dozu kolhicina ili prekinuti liječenje kolhicinom u bolesnika s normalnom funkcijom bubrega ili jetre.
Darunavir Mylan 150 mg film-coated tablets are white to off-white, capsule shaped, with two curved sides, marked with M on one side and DV2 on the other side.
Darunavir Mylan 150 mg filmom obložene tablete bijele su do gotovo bijele boje, duguljastog oblika s dvije zaobljene stranice i označene su s M na jednoj strani i DV2 na drugoj strani.
ART-naïve paediatric patients (3 to 17 years of age and weighing at least 40 kg) The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food.
Odrasli bolesnici koji nisu prethodno liječeni antiretrovirusnom terapijom (ART-om) Preporučeni režim doziranja je 800 mg jedanput na dan uz 150 mg kobicistata jedanput na dan ili 100 mg ritonavira jedanput na dan uzeto s hranom.
Darunavir Mylan 800 mg film-coated tablets are white to off-white, oval shaped, with two curved sides, marked with M on one side and DV8 on the other side.
Darunavir Mylan 800 mg filmom obložene tablete bijele su do gotovo bijele boje, ovalnog oblika s dvije zaobljene strane i označene su s M na jednoj strani i DV8 na drugoj strani.
For information on cobicistat, consult the cobicistat Summary of Product Characteristics.
Za informacije o kobicistatu, pročitajte Sažetak opisa svojstava lijeka za kobicistat.
Treatment-naïve darunavir/cobicistat 800/150 mg once daily + OBR N=295
Prethodno ne liječeni darunavir/kobicistat 800/150 mg jedanput na dan+ OOR N=295
Darunavir Mylan 300 mg film-coated tablets
Darunavir Mylan 300 mg filmom obložene tablete
The pharmacokinetics of darunavir in combination with ritonavir taken twice daily in 14 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 15 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir/ritonavir 600/100 mg twice daily (see section 4.2).
Farmakokinetika darunavira u kombinaciji s ritonavirom uzetih dva puta na dan, kod 14 prethodno liječenih pedijatrijskih bolesnika u dobi 3 do < 6 godina s težinom najmanje 15 kg do < 20 kg, pokazala je da doziranje ovisno o tjelesnoj težini rezultira izloženošću darunaviru koja je usporediva s onom kod odraslih koji primaju darunavir/ritonavir od 600/100 mg dva puta na dan (vidjeti dio 4.2).
problems with your balance - difficulty breathing, cough, nosebleed, throat irritation - inflammation of the stomach or mouth, heartburn, retching, dry mouth, discomfort of the abdomen, constipation, belching - kidney failure, kidney stones, difficult discharge of urine, frequent or excessive passage of urine, sometimes at night
problemi s ravnotežom - otežano disanje, kašalj, krvarenje iz nosa, nadraženost grla - upala želuca ili ustiju, žgaravica, dizanje želuca, suha usta, nelagoda u trbuhu, zatvor,
Co-administration with darunavir coadministered with cobicistat is not recommended (see section 4.4).
Ne preporučuje se istodobna primjena s darunavirom istodobno primijenjenim s kobicistatom (vidjeti dio 4.4).
darunavir/ ritonavir 800/100 mg once daily N=294
Darunavir/ ritonavir 800/100 mg jedanput na dan n=294
Concomitant use of darunavir with low dose ritonavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids)
Istodobna upotreba darunavira s niskom dozom ritonavira i kortikosteroida koje metabolizira CYP3A (npr. flutikazon propionat ili ostali inhalacijski ili nazalni kortikosteroidi) može povećati opasnost od razvoja sistemskih učinaka kortikosteroida uključujući Cushingov sindrom i adrenalnu supresiju.
When administration of rosuvastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety.
Kada je potrebno primijeniti rosuvastatin i pojačani darunavir, preporučuje se početi s najnižom mogućom dozom rosuvastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
When administration of rosuvastatin and darunavir coadministered with low dose ritonavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety.
Kada je potrebno primijeniti rosuvastatin i darunavir primijenjen istodobno s niskom dozom ritonavira, preporučuje se početi s najnižom mogućom dozom rosuvastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
Indinavir: comparison of indinavir/ritonavir 800/100 mg twice daily vs. indinavir/darunavir/ritonavir 800/400/100 mg twice daily.
Indinavir: usporedba indinavir/ritonavir 800/100 mg dva puta na dan vs. indinavir/darunavir/ritonavir 800/400/100 mg dva puta na dan Darunavir: usporedba darunavir/ritonavir 400/100 mg dva puta na dan vs. darunavir/ritonavir 400/100 mg u kombinaciji s indinavirom 800 mg dva puta na dan.
White to off-white, oval shaped, biconvex film coated tablets approximately 16.5 mm by 8.2 mm, debossed with 'M' on one side of the tablet and 'DV3' on other side.
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 16,5 mm × 8,2 mm s utisnutom oznakom „M” na jednoj strani i „DV3” na drugoj strani.
darunavir/ ritonavir 600/100 mg twice daily N=298
Darunavir/ ritonavir 600/100 mg dva puta na dan n=298
Darunavir Mylan 400 mg film-coated tablets are available blister packs containing 30 and 60 tablets and in the HDPE bottles of 60 and 100 tablets.
Darunavir Mylan 400 mg filmom obložene tablete dostupne su u blister pakiranjima koja sadržavaju 30 i 60 tableta i plastičnim bocama koje sadržavaju 60 i 100 tableta.
Darunavir Mylan 800 mg film-coated tablets darunavir
Darunavir Mylan 800 mg filmom obložene tablete darunavir
Name and address of the manufacturers responsible for batch release
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET Nazivi i adrese proizvođača odgovornih za puštanje serije lijeka u promet Mylan Hungary Kft
- In the evening, take one 600 milligram darunavir tablet together with 100 milligram ritonavir.
- Navečer uzmite jednu tabletu darunavira od 600 miligrama zajedno sa 100 miligrama ritonavira.
- In the morning, take one 600 milligram darunavir tablet together with 100 milligram ritonavir.
- Ujutro uzmite jednu tabletu darunavira od 600 miligrama zajedno sa 100 miligrama ritonavira.
Darunavir/ ritonavir 600/100 mg twice daily N=296
Darunavir/ ritonavir 600/100 mg dva puta na dan n=296
Darunavir Mylan 400 mg film-coated tablets darunavir
Darunavir Mylan 400 mg filmom obložene tablete darunavir
Ciclosporin Sirolimus Tacrolimus Everolimus
Ciklosporin Sirolimus
Darunavir Mylan 600 mg film-coated tablets darunavir
Darunavir Mylan 600 mg filmom obložene tablete darunavir
Darunavir Mylan 600 mg film-coated tablets are white to off-white, oval shaped, with two curved sides, marked with M on one side and DV5 on the other side.
Darunavir Mylan 600 mg filmom obložene tablete bijele su do gotovo bijele boje, ovalnog oblika s dvije zaobljene stranice i označene su s M na jednoj strani i DV5 na drugoj strani.
Darunavir/ritonavir 600/100 mg twice daily + OBR N=296
Darunavir/ritonavir 600/100 mg dva puta na dan + OOR n=296
Boosted darunavir and didanosine can be used without dose adjustments.
Pojačani darunavir se može primijeniti s didanozinom bez prilagodbe doze.
Darunavir Mylan 300 mg film-coated tablets are white to off-white, oval shaped, with two curved sides, marked with M on one side and DV3 on the other side.
Darunavir Mylan 300 mg filmom obložene tablete bijele su do gotovo bijele boje, ovalnog oblika s dvije zaobljene stranice i označene su s M na jednoj strani i DV3 na drugoj strani.
When administration of pravastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety.
Kada je potrebno primijeniti pravastatin i pojačani darunavir, preporučuje se početi s najnižom mogućom dozom pravastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
(drug) hypersensitivity immune reconstitution inflammatory syndrome
Upalni sindrom imunološke rekonstitucije
Darunavir Mylan 300 mg film-coated tablets darunavir
Darunavir Mylan 300 mg filmom obložene tablete darunavir
pravastatin Cmin ND pravastatin Cmax ↑ 63% an up to five-fold increase was seen in a limited subset of subjects
¶ kod limitirane podskupine ispitanika primijećeno je povišenje do pet puta
Darunavir co-administered with low dose ritonavir and raltegravir can be used without dose adjustments.
Darunavir istodobno primijenjen s niskom dozom ritonavira i raltegravirom može se primijeniti bez prilagodbe doze.
Efavirenz in combination with darunavir once daily may result in sub-optimal darunavir Cmin.
Efavirenz u kombinaciji s darunavirom može rezultirati suboptimalnom vrijednošću Cmin darunavira.
Darunavir Mylan 400 mg film-coated tablets are white to off-white, oval shaped with two curved sides, marked with M on one side and DV4 on the other side.
Darunavir Mylan 400 mg filmom obložene tablete bijele su do gotovo bijele boje, ovalnog oblika s dvije zaobljene stranice i označene su s M na jednoj strani i DV4 na drugoj strani.
Boosted darunavir is expected to increase these β-blocker plasma concentrations.
Očekuje se da će pojačani darunavir povećati koncentracije tih β-blokatora u plazmi. (CYP2D6 inhibicija)